Skip to main content
Main navigation
Home
About pCPA
Who We Are
Governance
Strategic Plan
pCPA Revitalization
FAQs
Negotiations
Recent Updates
Forms and Publications
Brand Name Drugs
Negotiations Status
Negotiation Process
Generic Drugs
Biologics/Biosimilars
Contact Us
EN
FR
Ultomiris (ravulizumab)
pCPA File Number:
21780
Negotiation Status:
Active Negotiation
Indication(s):
Paroxysmal nocturnal hemoglobinuria (PNH)
Sponsor/Manufacturer:
Alexion Pharma Canada Corp.
CADTH Project Number:
SR0700
pCPA Engagement Letter Issued:
2023-05-18
Negotiation Process Concluded:
Not Applicable